Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 104 entries
Sorted by: Best Match Show Resources per page
A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss.

Journal of primary care & community health

Tsai AG, Raube E, Conrad J, Bessesen DH, Rozwadowski JM.
PMID: 23804170
J Prim Care Community Health. 2012 Oct 01;3(4):251-5. doi: 10.1177/2150131912439893. Epub 2012 Mar 04.

OBJECTIVE: To compare the efficacy of a popular commercial program with that of a clinic-based intervention for weight loss.METHODS: Randomized clinical trial conducted at an internal medicine clinic affiliated with a city hospital in Denver, Colorado. Participant (n =...

Cite
Tsai AG, Raube E, Conrad J, et al. A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss. J Prim Care Community Health. 2012;3(4):251-5doi: 10.1177/2150131912439893.
Tsai, A. G., Raube, E., Conrad, J., Bessesen, D. H., & Rozwadowski, J. M. (2012). A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss. Journal of primary care & community health, 3(4), 251-5. https://doi.org/10.1177/2150131912439893
Tsai, Adam G, et al. "A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss." Journal of primary care & community health vol. 3,4 (2012): 251-5. doi: https://doi.org/10.1177/2150131912439893
Tsai AG, Raube E, Conrad J, Bessesen DH, Rozwadowski JM. A pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss. J Prim Care Community Health. 2012 Oct 01;3(4):251-5. doi: 10.1177/2150131912439893. Epub 2012 Mar 04. PMID: 23804170.
Copy Download .nbib Format: NLM
Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management

Goldenberg MM.
PMID: 23319844
P T. 2012 Dec;37(12):668-708.

Mirabegron (Myrbetriq) for overactive bladder; phentermine/topiramate ER (Qsymia) for weight management; and ocriplasmin injection (Jetrea) for vitreomacular adhesion.

Cite
Goldenberg MM. Pharmaceutical approval update. P T. 2012;37(12):668-708
Goldenberg, M. M. (2012). Pharmaceutical approval update. P & T : a peer-reviewed journal for formulary management, 37(12), 668-708.
Goldenberg, Marvin M. "Pharmaceutical approval update." P & T : a peer-reviewed journal for formulary management vol. 37,12 (2012): 668-708.
Goldenberg MM. Pharmaceutical approval update. P T. 2012 Dec;37(12):668-708. PMID: 23319844; PMCID: PMC3541862.
Copy Download .nbib Format: NLM
Heart failure induced by non-cardiac drugs.

Drug safety

Slørdal L, Spigset O.
PMID: 16808550
Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003.

Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely...

Cite
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86doi: 10.2165/00002018-200629070-00003.
Slørdal, L., & Spigset, O. (2006). Heart failure induced by non-cardiac drugs. Drug safety, 29(7), 567-86. https://doi.org/10.2165/00002018-200629070-00003
Slørdal, Lars, and Spigset, Olav. "Heart failure induced by non-cardiac drugs." Drug safety vol. 29,7 (2006): 567-86. doi: https://doi.org/10.2165/00002018-200629070-00003
Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29(7):567-86. doi: 10.2165/00002018-200629070-00003. PMID: 16808550.
Copy Download .nbib Format: NLM
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.

Therapeutic advances in neurological disorders

Schoonjans AS, Lagae L, Ceulemans B.
PMID: 26600876
Ther Adv Neurol Disord. 2015 Nov;8(6):328-38. doi: 10.1177/1756285615607726.

In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorders. Since the best available data are from the treatment of Dravet syndrome, we will focus primarily on this condition. Originally fenfluramine was launched as...

Cite
Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015;8(6):328-38doi: 10.1177/1756285615607726.
Schoonjans, A. S., Lagae, L., & Ceulemans, B. (2015). Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Therapeutic advances in neurological disorders, 8(6), 328-38. https://doi.org/10.1177/1756285615607726
Schoonjans, An-Sofie, et al. "Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome." Therapeutic advances in neurological disorders vol. 8,6 (2015): 328-38. doi: https://doi.org/10.1177/1756285615607726
Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015 Nov;8(6):328-38. doi: 10.1177/1756285615607726. PMID: 26600876; PMCID: PMC4643872.
Copy Download .nbib Format: NLM
Safety of antiobesity drugs.

Therapeutic advances in drug safety

Cheung BM, Cheung TT, Samaranayake NR.
PMID: 25114779
Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.

Obesity is a major health problem worldwide. Although diet and physical activity are crucial in the management of obesity, the long-term success rate is low. Therefore antiobesity drugs are of great interest, especially when lifestyle modification has failed. As...

Cite
Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4(4):171-81doi: 10.1177/2042098613489721.
Cheung, B. M., Cheung, T. T., & Samaranayake, N. R. (2013). Safety of antiobesity drugs. Therapeutic advances in drug safety, 4(4), 171-81. https://doi.org/10.1177/2042098613489721
Cheung, Bernard Man Yung, et al. "Safety of antiobesity drugs." Therapeutic advances in drug safety vol. 4,4 (2013): 171-81. doi: https://doi.org/10.1177/2042098613489721
Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721. PMID: 25114779; PMCID: PMC4125319.
Copy Download .nbib Format: NLM
Anti-Obesity Agents and the US Food and Drug Administration.

Current obesity reports

Casey MF, Mechanick JI.
PMID: 26626768
Curr Obes Rep. 2014 Sep;3(3):361-7. doi: 10.1007/s13679-014-0115-x.

Despite the growing market for obesity care, the US Food and Drug Administration (FDA) has approved only two new pharmaceutical agents-lorcaserin and combination phentermine/topiramate-for weight reduction since 2000, while removing three agents from the market in the same time...

Cite
Casey MF, Mechanick JI. Anti-Obesity Agents and the US Food and Drug Administration. Curr Obes Rep. 2014;3(3):361-7doi: 10.1007/s13679-014-0115-x.
Casey, M. F., & Mechanick, J. I. (2014). Anti-Obesity Agents and the US Food and Drug Administration. Current obesity reports, 3(3), 361-7. https://doi.org/10.1007/s13679-014-0115-x
Casey, Martin F, and Mechanick, Jeffrey I. "Anti-Obesity Agents and the US Food and Drug Administration." Current obesity reports vol. 3,3 (2014): 361-7. doi: https://doi.org/10.1007/s13679-014-0115-x
Casey MF, Mechanick JI. Anti-Obesity Agents and the US Food and Drug Administration. Curr Obes Rep. 2014 Sep;3(3):361-7. doi: 10.1007/s13679-014-0115-x. PMID: 26626768.
Copy Download .nbib Format: NLM
Phentermine/Topiramate extended-release capsules (qsymia) for weight loss.

P & T : a peer-reviewed journal for formulary management

Lonneman DJ, Rey JA, McKee BD.
PMID: 24222976
P T. 2013 Aug;38(8):446-52.

Phentermine/topiramate extended-release capsules (Qsymia) for weight loss.

Cite
Lonneman DJ, Rey JA, McKee BD. Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. P T. 2013;38(8):446-52
Lonneman, D. J., Rey, J. A., & McKee, B. D. (2013). Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. P & T : a peer-reviewed journal for formulary management, 38(8), 446-52.
Lonneman, David J, et al. "Phentermine/Topiramate extended-release capsules (qsymia) for weight loss." P & T : a peer-reviewed journal for formulary management vol. 38,8 (2013): 446-52.
Lonneman DJ, Rey JA, McKee BD. Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. P T. 2013 Aug;38(8):446-52. PMID: 24222976; PMCID: PMC3814438.
Copy Download .nbib Format: NLM
Phentermine, sibutramine and affective disorders.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

An H, Sohn H, Chung S.
PMID: 23678348
Clin Psychopharmacol Neurosci. 2013 Apr;11(1):7-12. doi: 10.9758/cpn.2013.11.1.7. Epub 2013 Apr 24.

A safe and effective way to control weight in patients with affective disorders is needed, and phentermine is a possible candidate. We performed a PubMed search of articles pertaining to phentermine, sibutramine, and affective disorders. We compared the studies...

Cite
An H, Sohn H, Chung S. Phentermine, sibutramine and affective disorders. Clin Psychopharmacol Neurosci. 2013;11(1):7-12doi: 10.9758/cpn.2013.11.1.7.
An, H., Sohn, H., & Chung, S. (2013). Phentermine, sibutramine and affective disorders. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 11(1), 7-12. https://doi.org/10.9758/cpn.2013.11.1.7
An, Hoyoung, et al. "Phentermine, sibutramine and affective disorders." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 11,1 (2013): 7-12. doi: https://doi.org/10.9758/cpn.2013.11.1.7
An H, Sohn H, Chung S. Phentermine, sibutramine and affective disorders. Clin Psychopharmacol Neurosci. 2013 Apr;11(1):7-12. doi: 10.9758/cpn.2013.11.1.7. Epub 2013 Apr 24. PMID: 23678348; PMCID: PMC3650299.
Copy Download .nbib Format: NLM
Phentermine-topiramate: First combination drug for obesity.

International journal of applied & basic medical research

Singh J, Kumar R.
PMID: 26097830
Int J Appl Basic Med Res. 2015 May-Aug;5(2):157-8. doi: 10.4103/2229-516X.157177.

Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted...

Cite
Singh J, Kumar R. Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res. 2015;5(2):157-8doi: 10.4103/2229-516X.157177.
Singh, J., & Kumar, R. (2015). Phentermine-topiramate: First combination drug for obesity. International journal of applied & basic medical research, 5(2), 157-8. https://doi.org/10.4103/2229-516X.157177
Singh, Jagjit, and Kumar, Rajiv. "Phentermine-topiramate: First combination drug for obesity." International journal of applied & basic medical research vol. 5,2 (2015): 157-8. doi: https://doi.org/10.4103/2229-516X.157177
Singh J, Kumar R. Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res. 2015 May-Aug;5(2):157-8. doi: 10.4103/2229-516X.157177. PMID: 26097830; PMCID: PMC4456896.
Copy Download .nbib Format: NLM
Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months.

Journal of personalized medicine

Rocha-González HI, De la Cruz-Álvarez LE, Kammar-García A, Canizales-Quinteros S, Huerta-Cruz JC, Barranco-Garduño LM, Reyes-García JG.
PMID: 34945825
J Pers Med. 2021 Dec 12;11(12). doi: 10.3390/jpm11121354.

The efficacy of anti-obesity drugs usually does not consider the high degree of interindividual variability in responses to the drug which could affect the decision to withdraw the drug early due to ineffectiveness or to continue therapy according to...

Cite
Rocha-González HI, De la Cruz-Álvarez LE, Kammar-García A, et al. Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months. J Pers Med. 2021;11(12)doi: 10.3390/jpm11121354.
Rocha-González, H. I., De la Cruz-Álvarez, L. E., Kammar-García, A., Canizales-Quinteros, S., Huerta-Cruz, J. C., Barranco-Garduño, L. M., & Reyes-García, J. G. (2021). Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months. Journal of personalized medicine, 11(12), . https://doi.org/10.3390/jpm11121354
Rocha-González, Héctor Isaac, et al. "Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months." Journal of personalized medicine vol. 11,12 (2021). doi: https://doi.org/10.3390/jpm11121354
Rocha-González HI, De la Cruz-Álvarez LE, Kammar-García A, Canizales-Quinteros S, Huerta-Cruz JC, Barranco-Garduño LM, Reyes-García JG. Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months. J Pers Med. 2021 Dec 12;11(12). doi: 10.3390/jpm11121354. PMID: 34945825.
Copy Download .nbib Format: NLM
Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.

JAMA network open

Pantalone KM, Smolarz BG, Ramasamy A, Baz Hecht M, Harty BJ, Rogen B, Griebeler ML, Borukh E, Young JB, Burguera B.
PMID: 34255049
JAMA Netw Open. 2021 Jul 01;4(7):e2116595. doi: 10.1001/jamanetworkopen.2021.16595.

IMPORTANCE: The clinical efficacy of antiobesity medications (AOMs) as adjuncts to lifestyle intervention is well characterized, but data regarding their use in conjunction with workplace wellness plans are lacking, and coverage of AOMs by US private employers is limited.OBJECTIVE:...

Cite
Pantalone KM, Smolarz BG, Ramasamy A, et al. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(7):e2116595doi: 10.1001/jamanetworkopen.2021.16595.
Pantalone, K. M., Smolarz, B. G., Ramasamy, A., Baz Hecht, M., Harty, B. J., Rogen, B., Griebeler, M. L., Borukh, E., Young, J. B., & Burguera, B. (2021). Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial. JAMA network open, 4(7), e2116595. https://doi.org/10.1001/jamanetworkopen.2021.16595
Pantalone, Kevin M, et al. "Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial." JAMA network open vol. 4,7 (2021): e2116595. doi: https://doi.org/10.1001/jamanetworkopen.2021.16595
Pantalone KM, Smolarz BG, Ramasamy A, Baz Hecht M, Harty BJ, Rogen B, Griebeler ML, Borukh E, Young JB, Burguera B. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial. JAMA Netw Open. 2021 Jul 01;4(7):e2116595. doi: 10.1001/jamanetworkopen.2021.16595. PMID: 34255049; PMCID: PMC8278271.
Copy Download .nbib Format: NLM
Is There a Prescription to Treat Pediatric Obesity?.

American journal of lifestyle medicine

Srivastava SB.
PMID: 31903078
Am J Lifestyle Med. 2019 Oct 24;14(1):36-39. doi: 10.1177/1559827619881095. eCollection 2020.

Pediatric obesity is complex-in every way. The pathogenesis, which is a result of a multitude of factors combined with social and environmental factors makes it a crisis with overwhelming challenges. It is difficult to treat pediatric obesity; however, guidelines...

Cite
Srivastava SB. Is There a Prescription to Treat Pediatric Obesity?. Am J Lifestyle Med. 2019;14(1):36-39doi: 10.1177/1559827619881095.
Srivastava, S. B. (2020). Is There a Prescription to Treat Pediatric Obesity?. American journal of lifestyle medicine, 14(1), 36-39. https://doi.org/10.1177/1559827619881095
Srivastava, Sneha Baxi. "Is There a Prescription to Treat Pediatric Obesity?." American journal of lifestyle medicine vol. 14,1 (2020): 36-39. doi: https://doi.org/10.1177/1559827619881095
Srivastava SB. Is There a Prescription to Treat Pediatric Obesity?. Am J Lifestyle Med. 2019 Oct 24;14(1):36-39. doi: 10.1177/1559827619881095. eCollection 2020. PMID: 31903078; PMCID: PMC6933557.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 104 entries